Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals
Open Access
- 25 April 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4), e0216075
- https://doi.org/10.1371/journal.pone.0216075
Abstract
To understand preferences for and estimate the likely uptake of preventive treatments currently being evaluated in randomized controlled trials with individuals at increased risk of developing rheumatoid arthritis (RA). Focus groups were used to identify key attributes of potential preventive treatment for RA (reduction in risk of RA, how treatment is taken, chance of side effects, certainty in estimates, health care providers opinion). A web-based discrete choice experiment (DCE) was administered to people at-risk of developing RA, asking them to first choose their preferred of two hypothetical preventive RA treatments, and then between their preferred treatment and ‘no treatment for now.’ DCE data was analyzed using conditional logit regression to estimate the significance and relative importance of attributes in influencing preferences. Two-hundred and eighty-eight first-degree relatives (60% female; 66% aged 18–39 years) completed all tasks in the survey. Fourteen out of fifteen attribute levels significantly influenced preferences for treatments. How treatment is taken (oral vs. infusion β0.983, p<0.001), increasing reduction in risk of RA (β0.922, p<0.001), health care professional preference (β0.900, p<0.001), and avoiding irreversible (β0.839, p<0.001) or reversible serious side effects (β0.799, p<0.001) were most influential. Predicted uptake was high for non-biologic drugs (e.g. 84% hydroxycholoroquine), but very low for atorvastatin (8%) and biologics (<6%). Decisions to take preventative treatments are complex, and uptake depends on how treatments can compromise on convenience, potential risks and benefits, and recommendations/preferences of health care professionals. This evidence contributes to understanding whether different preventative treatment strategies are likely to be acceptable to target populations.Keywords
Funding Information
- CIORA
This publication has 40 references indexed in Scilit:
- Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort studyBMJ, 2012
- Environmental and Gene-Environment Interactions and Risk of Rheumatoid ArthritisRheumatic Disease Clinics of North America, 2012
- EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals Of The Rheumatic Diseases, 2012
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- The online laboratory: conducting experiments in a real labor marketExperimental Economics, 2011
- Amazon's Mechanical TurkPerspectives on Psychological Science, 2011
- Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)Annals Of The Rheumatic Diseases, 2009
- Valuing Experience Factors in the Provision of Chlamydia Screening: An Application to Women Attending the Family Planning ClinicValue in Health, 2009
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Discrete choice experiments in health careBMJ, 2004